These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32425303)

  • 21. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 24. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
    Cadegiani FA
    Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
    [No Abstract]   [Full Text] [Related]  

  • 26. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
    Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
    N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
    [No Abstract]   [Full Text] [Related]  

  • 27. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.
    McPherson SW; Keunen JE; Bird AC; Chew EY; van Kuijk FJ
    Am J Ophthalmol; 2020 Aug; 216():A5-A6. PubMed ID: 32505362
    [No Abstract]   [Full Text] [Related]  

  • 28. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
    Bose RJC; McCarthy JR
    Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
    [No Abstract]   [Full Text] [Related]  

  • 29. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
    Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
    J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
    [No Abstract]   [Full Text] [Related]  

  • 31. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
    Ciulla MM
    Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
    [No Abstract]   [Full Text] [Related]  

  • 32. Apelin-potential therapy for COVID-19?
    Saeedi Saravi SS; Beer JH
    J Mol Cell Cardiol; 2020 Aug; 145():84-87. PubMed ID: 32562701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 and the RAAS-a potential role for angiotensin II?
    Busse LW; Chow JH; McCurdy MT; Khanna AK
    Crit Care; 2020 Apr; 24(1):136. PubMed ID: 32264922
    [No Abstract]   [Full Text] [Related]  

  • 34. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
    Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
    Somanath PR
    Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L45-L47. PubMed ID: 32519895
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Choudhary S; Silakari O
    Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and the cardiovascular system.
    Zheng YY; Ma YT; Zhang JY; Xie X
    Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
    Nicolau LAD; Nolêto IRSG; Medeiros JVR
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
    [No Abstract]   [Full Text] [Related]  

  • 40. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking.
    Joshi T; Joshi T; Sharma P; Mathpal S; Pundir H; Bhatt V; Chandra S
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4529-4536. PubMed ID: 32373991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.